Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma (PR Newswire)
Posted on June 1, 2008 at 11:38 am in Online Trading
Medarex, Inc. today announced updated long-term follow-up and overall survival results from a Phase 2 clinical study of 3 mg/kg of ipilimumab in combination with dacarbazine where 11.4%, or 4 of 35 patients, were still alive at or greater than 4 years of follow-up.
More: continued here
